This study is designed as a long-term follow-up study of participants who have receive
genetically modified autologous CLBR001 CAR-T cells
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT04488354.
Patients will be enrolled following either the completion or early
termination/discontinuation from Study NCT04450069 or any protocol in which patients were
administered CLBR001. Patients will begin the long-term follow-up period regardless of
whether they responded to treatment or progressed on treatment. Patients will be followed
for up to 15 years post CLBR001 infusion and will continue to be monitored for safety,
immunogenicity, and efficacy.
Trial PhasePhase I
Trial TypeNot provided by clinicaltrials.gov
Lead OrganizationCalibr, a division of Scripps Research
